Clinical Trial Update: Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring [Phase 4]

View source ↗

Summary

A Phase 4 trial investigating cardiovascular risk after converting kidney transplant recipients to full-dose Myfortic and Neoral with two-hour post-dose monitor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• End-stage Renal Disease

Drugs mentioned

• MYFORTIC (MYCOPHENOLIC ACID)
• NEORAL (CYCLOSPORINE)

Snippet

Sponsor: University of Saskatchewan | Conditions: Cardiovascular Disease, Cardiovascular Outcomes | Phase 4 | Status: WITHDRAWN